Zura Bio Ltd
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
ZURA$1.41+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(50,527) | $(33,435) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Share-based compensation expense | 9,465 | 7,376 |
| Deferred income taxes | (2,753) | — |
| Depreciation and amortization | 32 | 20 |
| Foreign exchange transaction loss | 46 | 67 |
| Loss on disposal of property and equipment | 5 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,343) | (249) |
| Other assets | 1,511 | — |
| Accounts payable and accrued expenses | 3,740 | (872) |
| Net cash used in operating activities | (39,824) | (27,093) |
| Cash flows from investing activities | ||
| Purchase of property and equipment | (37) | (64) |
| Net cash used in investing activities | (37) | (64) |
| Cash flows from financing activities | ||
| Proceeds from issuance of Class A Ordinary Shares in connection with February 2026 Equity Offering, net of $8.5 million of underwriters’ fees and discounts | 123,371 | — |
| Proceeds from issuance of Pre-Funded Warrants in connection with February 2026 Equity Offering, net of $0.7 million of underwriters’ fees and discounts | 11,202 | — |
| Proceeds from issuance of Class A Ordinary Shares in connection with a sale under the ATM, net of $0.2 million of commissions | — | 5,093 |
| Payment of employee withholding taxes for restricted stock units withheld | — | (34) |
| Proceeds from exercise of stock options | 1,015 | 90 |
| Net cash provided by financing activities | 135,588 | 5,149 |
| Net increase (decrease) in cash and cash equivalents | 95,727 | (22,008) |
| Cash and cash equivalents, beginning of period | 109,407 | 176,498 |
| Cash and cash equivalents, end of period | $205,134 | $154,490 |
| Supplemental Disclosure | ||
| Cash paid for taxes | $— | $— |
| Cash paid for interest | $— | $— |
| Supplemental Disclosure of Non-Cash Investing and Financing Activities | ||
| Purchase of property and equipment included in accounts payable and accrued expenses | $23 | $12 |
| Restricted stock units withheld to pay employee withholding taxes | $99 | $— |
| Stock option exercise proceeds receivable | $1,120 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.